RESEARCHER PROFILE (Filmed May 2024)
Dr Shelley Keating AES AEP ESSAM
Senior Lecturer, Clinical Exercise Physiology and Accredited Exercise Physiologist
School of Human Movement and Nutrition Sciences
The University of Queensland
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
Dr Keating has an established research profile that is delivering impact for patients and clinicians. Her research has led to the development of safe and feasible exercise programs that generate significant improvement in the cardiometabolic health of individuals with MASLD and related chronic disease. Drawing on these findings, Dr Keating has developed national and international exercise guidelines for MASLD. Her research has led to a paradigm shift in how exercise is prioritised in MASLD management and has been adopted into exercise prescription recommendations in 15 international guidelines for MASLD management across 12 countries.
Dr Keating’s research had found a lack of awareness, uptake, and sustainability of exercise for MASLD management. Her ongoing program of research is informed by, and co-designed with, people with MASLD and related chronic disease, to find sustainable exercise solutions.
Her contribution to the field was recognised by the prestigious 2020 Australia and New Zealand Obesity Society Young Investigator award. Shelley has been an ESSA (Exercise & Sports Science Australia) member since 2007 and has 16 years of clinical AEP experience in people with cardiometabolic disease including MAFLD.
Her mission is to change the way that exercise is prioritised, accessed, and delivered to improve the health and wellbeing of people with MASLD and related type 2 diabetes.
Source: Supplied & ESSA (Exercise & Sports Science Australia)
Note: AES is the acronym for Accredited Exercise Scientist (AES), AEP is the acronym for Accredited Exercise Physiologist, ESSAM is the acronym for Exercise & Sports Science Australia Member.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Genetic disease research imitating function and architecture of organs
Professor Wolvetang was among the first to bring the first human embryonic stem cells to Queensland, with his Wolvetang Group at the AIBN now renowned for its work with organoids: growing them, studying them, and using them to try and understand diseases and human development.
Using cutting edge technology, Professor Wolvetang designs and grows organoids both for their own work and for labs across the country, coaxing pluripotent stem cells or tissue samples into 3D structures that mimic the function and architecture of real brains, livers, kidneys, spinal cords, and intestines.
-
Dr Paul Griffin
MATER HEALTH SERVICES, QUEENSLAND, AUSTRALIA
